

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 9, 2011

Commission File Number: 333171722

ACADIA Pharmaceuticals Inc.

(Exact name of small business issuer as specified in its charter)

Delaware

061376651

(State or other jurisdiction of incorporation or organization)

(IRS Employer Identification No.)

3911 Sorrento Valley Blvd, San Diego, California 92121
(Address of principal executive offices)

858-558-2871

(Registrant's Telephone number)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On November 9, 2011, ACADIA Pharmaceuticals Inc. (the "Company") issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2011. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibit is furnished herewith:

99.1 Press release dated November 9, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACADIA Pharmaceuticals Inc.

Date: *November 9, 2011*

By: */s/ Thomas H. Aasen*

*Name: Thomas H. Aasen
Title: Executive Vice President, Chief Financial
Officer and Chief Business Officer*

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
EX-99.1	Press Release dated November 9, 2011

Contact:
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive Vice President,
Chief Financial Officer and Chief Business Officer
(858) 558-2871

ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2011 FINANCIAL RESULTS

SAN DIEGO, CA November 9, 2011 – ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2011.

ACADIA reported a net loss of \$5.1 million, or \$0.10 per common share, for the third quarter of 2011 compared to a net loss of \$4.2 million, or \$0.11 per common share, for the third quarter of 2010. For the nine months ended September 30, 2011, ACADIA reported a net loss of \$17.5 million, or \$0.34 per common share, compared to a net loss of \$14.0 million, or \$0.37 per common share, for the comparable period of 2010.

At September 30, 2011, ACADIA's cash, cash equivalents and investment securities totaled \$36.2 million compared to \$37.1 million at December 31, 2010. ACADIA continues to expect that its existing cash resources and anticipated payments from its collaborations will be sufficient to fund its operations at least into the first half of 2013.

“For ACADIA, 2011 has been highlighted by solid progress in the execution of the ongoing pivotal trial in our Phase III Parkinson's disease psychosis program with pimavanserin, the strengthening of our cash runway, and the recent advancement of AM-831, our new product candidate for schizophrenia, into the clinic,” said Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer. “We look forward to building on this momentum as we close out the year and embark on what we expect to be an exciting and value-driving 2012.”

Revenues totaled \$584,000 for the third quarter of 2011 compared to \$2.3 million for the third quarter of 2010. This decrease was primarily due to the conclusion of ACADIA's collaboration with Biovail in October 2010. ACADIA recognized \$1.7 million in revenues from that collaboration in the third quarter of 2010.

Research and development expenses decreased to \$4.2 million for the third quarter of 2011, including \$129,000 in stock-based compensation, from \$5.0 million for the third quarter of 2010, including \$133,000 in stock-based compensation. This decrease was primarily due to savings in facilities and other costs associated with ACADIA's research and development organization as well as lower external service costs.

General and administrative expenses totaled \$1.5 million for the third quarter of 2011, including \$272,000 in stock-based compensation, compared to \$1.6 million for the third quarter of 2010, including \$260,000 in stock-based compensation.

Conference Call and Webcast Information

ACADIA management will review its third quarter financial results and development programs via conference call and webcast later today at 5:00 p.m. Eastern Time. The conference call may be accessed by dialing 866-711-8198 for participants in the U.S. or Canada and 617-597-5327 for international callers (reference passcode 10252163). A telephone replay of the conference call may be accessed through November 23, 2011 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 14223099). The conference call also will be webcast live on ACADIA's website, www.acadia-pharm.com, under the investors section and will be archived there until November 23, 2011.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA has four product candidates in clinical development including pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. ACADIA also has a product candidate in Phase II development for chronic pain and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc., and AM-831 in Phase I development for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd. All of the product candidates in ACADIA's pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIA's drug discovery and development programs, including clinical trials and the results therefrom, the potential of and the benefits to be derived from product candidates, in each case including pimavanserin, value-driving events in 2012, and the period during which ACADIA's cash resources will be sufficient to fund its operations. These statements are only predictions based on current information and expectations and involve a number of

risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, collaborations with others, variations in expenses and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA's annual report on Form 10-K for the year ended December 31, 2010 as well as ACADIA's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

ACADIA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	<u>2011</u>	<u>2010</u>	<u>2011</u>	<u>2010</u>
Collaborative revenues	\$ 584	\$ 2,301	\$ 1,479	\$ 6,731
Operating expenses				
Research and development (includes stock-based compensation of \$129, \$133, \$383 and \$512, respectively)	4,158	4,965	12,885	15,822
General and administrative (includes stock-based compensation of \$272, \$260, \$807 and \$735, respectively)	<u>1,519</u>	<u>1,578</u>	<u>6,132</u>	<u>4,944</u>
Total operating expenses	<u>5,677</u>	<u>6,543</u>	<u>19,017</u>	<u>20,766</u>
Loss from operations	(5,093)	(4,242)	(17,538)	(14,035)
Interest income, net	<u>17</u>	<u>15</u>	<u>73</u>	<u>33</u>
Net loss	\$ (5,076)	\$ (4,227)	\$ (17,465)	\$ (14,002)
Net loss per common share, basic and diluted	\$ (0.10)	\$ (0.11)	\$ (0.34)	\$ (0.37)
Weighted average common shares outstanding, basic and diluted	<u>52,800</u>	<u>38,383</u>	<u>51,963</u>	<u>38,355</u>

ACADIA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(Unaudited)

	September 30, <u>2011</u>	December 31, <u>2010(1)</u>
Assets		
Cash, cash equivalents and investment securities	\$ 36,150	\$ 37,087
Prepaid expenses, receivables and other current assets	<u>613</u>	<u>762</u>
Total current assets	36,763	37,849
Property and equipment, net	181	426
Other assets	<u>78</u>	<u>119</u>
Total assets	\$ <u>37,022</u>	\$ <u>38,394</u>
Liabilities and Stockholders' Equity		
Current liabilities	6,409	5,959
Long-term portion of deferred revenue	2,441	2,623
Other long-term liabilities	<u>28</u>	<u>124</u>
Total liabilities	8,878	8,706
Stockholders' equity	<u>28,144</u>	<u>29,688</u>
Total liabilities and stockholders' equity	\$ <u>37,022</u>	\$ <u>38,394</u>

- (1) The condensed consolidated balance sheet at December 31, 2010 was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America.